This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-0636v1 68/15/6453    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beeghly-Fadiel, A. Articles by Zheng, W. Search for Related Content PubMed PubMed Citation Articles by Beeghly-Fadiel, A. Articles by Zheng, W.

Common MMP-7 Polymorphisms and Breast Cancer Susceptibility: A Multistage Study of Association and Functionality

¹ Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine and ² Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee; and ³ Department of Epidemiology, Shanghai Cancer Institute and ⁴ Shanghai Center for Disease Prevention and Control, Shanghai, China

Requests for reprints: Wei Zheng, Vanderbilt Epidemiology Center, Institute of Medicine & Public Health, Vanderbilt University Medical Center, 2525 West End Avenue, 8th Floor, Nashville, TN 37203-1738. Phone: 615-936-0682; Fax: 615-936-8241; E-mail: wei.zheng{at}vanderbilt.edu.

Key Words: breast cancer • epidemiology • genetic susceptibility • MMP-7 • polymorphisms • SNPs

Matrix metalloproteinase-7 (MMP-7) is a small secreted proteolytic enzyme with broad substrate specificity against ECM and non-ECM components. Known to be vital for tumor invasion and metastasis, accumulating evidence also implicates MMP-7 in cancer development. Using data from the Shanghai Breast Cancer Study, we conducted a two-stage study to evaluate the association of MMP-7 single nucleotide polymorphisms (SNPs) with breast cancer risk. Additionally, associated SNPs were characterized by laboratory assays. In stage 1, 11 SNPs were genotyped among 1,079 incident cases and 1,082 community controls using an Affymetrix Genotyping System. Promising SNPs were selected for stage 2 evaluation and genotyped by TaqMan allelic discrimination assays in an independent set of 1,911 cases and 1,811 controls. Three SNPs were selected for stage 2 validation (rs880197, rs10895304, and rs12184413); one had highly consistent results between the two stages of the study. In combined analysis, homozygosity for the variant T allele for rs12184413 was associated with an odds ratio (OR) of 0.7 [95% confidence interval (95% CI), 0.6–0.9] compared with the common C allele. This effect was slightly more pronounced in postmenopausal women (OR, 0.6; 95% CI, 0.4–0.8) than in premenopausal women (OR, 0.8; 95% CI, 0.6–1.1). This SNP is located 3' of the MMP-7 gene, in an area enriched with CTCF binding sites. In silico analysis suggested a regulatory role for this region, and our in vitro assays showed an allelic difference in nuclear protein binding capacity. Results from our study suggest that common MMP-7 genetic polymorphisms may contribute to breast cancer susceptibility. [Cancer Res 2008;68(15):6453–9]

This article has been cited by other articles:

				T. A. O'Mara, J. A. Clements, and A. B. Spurdle The Use of Predictive or Prognostic Genetic Biomarkers in Endometrial and Other Hormone-Related Cancers: Justification for Extensive Candidate Gene Single Nucleotide Polymorphism Studies of the Matrix Metalloproteinase Family and their Inhibitors Cancer Epidemiol. Biomarkers Prev., September 1, 2009; 18(9): 2352 - 2365. [Abstract] [Full Text] [PDF]

				A. Beeghly-Fadiel, Y.-B. Xiang, S. L. Deming, J.-R. Long, W.-H. Xu, Q. Cai, W. Zheng, and X. O. Shu No Association between Matrix Metalloproteinase (MMP)-1, MMP-3, and MMP-7 SNPs and Endometrial Cancer Risk Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1925 - 1928. [Full Text] [PDF]

				A. Beeghly-Fadiel, W. Lu, J.-R. Long, X.-o. Shu, Y. Zheng, Q. Cai, Y.-T. Gao, and W. Zheng Matrix Metalloproteinase-2 Polymorphisms and Breast Cancer Susceptibility Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1770 - 1776. [Abstract] [Full Text] [PDF]

				A. Beeghly-Fadiel, Q. Cai, W. Lu, J. Long, Y.-T. Gao, X.-o. Shu, and W. Zheng No Association between Matrix Metalloproteinase-1 or Matrix Metalloproteinase-3 Polymorphisms and Breast Cancer Susceptibility: A Report from the Shanghai Breast Cancer Study Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1324 - 1327. [Full Text] [PDF]

				Y.-S. Hong, S. L. Deming, Y.-T. Gao, J.-R. Long, X.-O. Shu, Q. Cai, W. Lu, and W. Zheng A Two-stage Case-Control Study of EGFR Polymorphisms and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 680 - 683. [Full Text] [PDF]